There are many factors in the development of colon cancer, and its clinical symptoms may not show up in the early stage, but in the middle and late stages, there may be abdominal pain, mucopurulent stool, constipation, intestinal obstruction, lymphatic metastasis, etc. According to the data, the incidence and mortality rate of human colon cancer are 10.2 and 9.2%, respectively, ranking second in the new incidence and mortality rate of cancer ( Siegel et al., 2017 Sung et al., 2021). In recent years, the incidence rate of colon cancer has been increasing year by year, and the incidence rate in young people has increased rapidly ( Benson et al., 2018). This will deepen our understanding of the potential mechanisms of PD anticolon cancer and establish a foundation for further basic experimental research.Ĭolon cancer is a common malignant tumor of the gastrointestinal tract that originates in the mucosal epithelium of the colon. The docking results showed good affinity, especially quercetin.Ĭonclusion: This study preliminarily verified that PD may exert its effect on the treatment of colon cancer through multi-ingredients, multitargets, and multipathways. We further selected core targets with high degree values as receptor proteins for molecular docking with the main active ingredients of the drug, including MAPK1, JUN, and AKT1. The results of KEGG analysis indicated that the PI3K-Akt signaling pathway, MAPK signaling pathway, proteoglycans in cancer, IL-17 signaling pathway, cellular senescence, and TNF signaling pathway were mainly involved in the regulation of tumor cells. The results of GO analysis showed that PD anticolon cancer may be related to cell proliferation, apoptosis, energy metabolism, immune regulation, signal transduction, and other biological processes. Results: Sixty-five ingredients containing 188 nonrepetitive targets were screened and 180 potential targets of PD anticolon cancer were identified, including 10 core targets, namely, MAPK1, JUN, AKT1, TP53, TNF, RELA, MAPK14, CXCL8, ESR1, and FOS. Molecular docking was implemented using AutoDockTools to predict the binding capacity for the core targets and the active components in PD.
ELUCIDATE THE MECHANIMS SOFTWARE
Cytoscape software was used to construct the “Components–Targets–Pathway” map, and the String database was used to analyze the protein interaction network of the intersecting targets and screen the core targets, and then, the core targets were analyzed using Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses. Then, the screened drug and disease targets were Venn analyzed to obtain the intersection targets. Methods: Based on the Traditional Chinese Medicine Systems Pharmacology Database, the main targets and active ingredients in PD were filtered, and then, the colon cancer-related targets were screened using Genecards, OMIM, PharmGKB, and Drugbank databases. This study is based on the analytical methods of network pharmacology and molecular docking to study the mechanism of PD in the treatment of colon cancer. Pulsatilla decoction (PD) has some therapeutic effects on colon cancer. Objective: Colon cancer is a malignant neoplastic disease that seriously endangers the health of patients.
0 kommentar(er)
